Published in J Dev Behav Pediatr on October 01, 2013
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension (2012) 5.60
Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med (2010) 4.40
Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension (2004) 4.38
Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. Hypertension (2007) 2.63
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension (2005) 2.54
Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. Diabetes Care (2005) 2.26
Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects. Diabetes Care (2003) 2.12
Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol (2006) 2.02
Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens (2007) 1.97
Prognostic significance of isolated, non-specific left ventricular repolarization abnormalities in hypertension. J Hypertens (2004) 1.56
Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J Invest Dermatol (2011) 1.51
Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J (2009) 1.47
Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens (2007) 1.43
Blood pressure lowering in the oldest old. J Hypertens (2010) 1.40
The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens (2009) 1.38
Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension (2009) 1.16
Masked hypertension: evaluation, prognosis, and treatment. Am J Hypertens (2010) 1.12
Contribution of the ABP-International study to the definition of night-time tachycardia. J Hypertens (2014) 1.07
Insulin is required for prandial ghrelin suppression in humans. Diabetes (2003) 1.05
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. J Hypertens (2014) 1.04
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis (2005) 1.03
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia. Diabetes (2002) 1.01
Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens (2010) 0.98
Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol (2002) 0.97
Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens (2014) 0.96
Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag (2009) 0.94
Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 0.92
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag (2008) 0.90
Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens (2002) 0.90
New-onset diabetes, antihypertensive treatment, and outcome. Hypertension (2007) 0.90
Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens (2003) 0.90
Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis (2010) 0.88
Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr Cardiol Rep (2012) 0.87
Circulating ghrelin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 0.87
Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol (2003) 0.87
Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol (2013) 0.86
Mutual interactions between depression/quality of life and adherence to a multidisciplinary lifestyle intervention in obesity. J Clin Endocrinol Metab (2012) 0.86
White-coat hypertension in adults. Blood Press Monit (2005) 0.86
Strategies to enhance compliance to physical activity for patients with insulin resistance. Appl Physiol Nutr Metab (2007) 0.86
Is the definition of daytime and nighttime blood pressure prognostically relevant? Blood Press Monit (2008) 0.85
Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol (2011) 0.85
Plasma ghrelin concentrations, food intake, and anorexia in liver failure. J Clin Endocrinol Metab (2004) 0.84
New-onset hyperglycemia and acute coronary syndrome: a systematic overview and meta-analysis. Curr Diabetes Rev (2010) 0.84
ß-Blockers reduce mortality in patients undergoing high-risk non-cardiac surgery. Am J Cardiovasc Drugs (2010) 0.84
The 'Echo Heart Failure Score': an echocardiographic risk prediction score of mortality in systolic heart failure. Eur J Heart Fail (2013) 0.83
Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. Expert Opin Drug Saf (2012) 0.82
Effects of a multidisciplinary lifestyle intervention for obesity on mental and physical components of quality of life: the mediatory role of depression. Psychol Rep (2013) 0.82
"The lower the BP the better" paradigm in the elderly: vanished by VALISH? Hypertension (2010) 0.82
Aggressive blood pressure lowering is dangerous: the J-curve: con side of the arguement. Hypertension (2014) 0.81
Effect of revascularizing viable myocardium on left ventricular diastolic function in patients with ischaemic cardiomyopathy. Eur Heart J (2009) 0.81
Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. Expert Opin Drug Saf (2014) 0.81
Statins in acute coronary syndrome: very early initiation and benefits. Ther Adv Cardiovasc Dis (2012) 0.81
Fixed-dose combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev (2012) 0.80
Short-term treatment with low doses of recombinant human GH stimulates lipolysis in visceral obese men. J Clin Endocrinol Metab (2002) 0.80
The clinical significance of white-coat and masked hypertension. Blood Press Monit (2007) 0.80
Attachment pattern and cognitive skills: an exploratory study in an Italian non-clinical sample. Percept Mot Skills (2013) 0.80
"From apennines to andes:" does body mass index affect the relationship between age and blood pressure? Hypertension (2012) 0.79
Hypertension around the world: new insights from developing countries. J Hypertens (2013) 0.79
Beta-blockers and risk of all-cause mortality in non-cardiac surgery. Ther Adv Cardiovasc Dis (2010) 0.79
Fine needle aspiration coupled with real-time PCR: a painless methodology to study adaptive functional changes in skeletal muscle. Nutr Metab Cardiovasc Dis (2007) 0.79
Diuretic treatment of hypertension. Diabetes Care (2011) 0.79
Fluid and electrolyte balance after major thoracic surgery by bioimpedance and endocrine evaluation. Eur J Cardiothorac Surg (2011) 0.79
Angiotensin receptor blockers in hypertension. New insights from Japan. Hypertens Res (2010) 0.79
Neutrophil count and ambulatory pulse pressure as predictors of cardiovascular adverse events in postmenopausal women with hypertension. Am J Hypertens (2011) 0.79
Prognostic value of circadian blood pressure changes in relation to differing measures of day and night. J Am Soc Hypertens (2010) 0.79
Hypertension, inflammation and atrial fibrillation. J Hypertens (2014) 0.79
Left ventricular hypertrophy and obesity: only a matter of fat? High Blood Press Cardiovasc Prev (2014) 0.78
Hypertensive disorders during pregnancy: clinical applicability of risk prediction models. J Hypertens (2011) 0.78
Above which blood pressure level does the risk of atrial fibrillation increase? Hypertension (2012) 0.78
Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf (2012) 0.78
Electrocardiographic abnormalities of left ventricular repolarization: prognostic implications in hypertensive post-menopausal women. Maturitas (2010) 0.78
Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis (2012) 0.78
Antecedents and consequences of fear of childbirth in nulliparous and parous women. Infant Ment Health J (2014) 0.77
Is the development of diabetes with antihypertensive therapy a problem?--Pro. J Clin Hypertens (Greenwich) (2006) 0.77
Retrovirus-like long-terminal repeat DQ-LTR13 and genetic susceptibility to type 1 diabetes and autoimmune Addison's disease. Diabetes (2005) 0.77
Treatment strategies for osteoarthritis patients with pain and hypertension. Ther Adv Musculoskelet Dis (2010) 0.77
Prognostic impact of sex-ambulatory blood pressure interactions in 10 cohorts of 17 312 patients diagnosed with hypertension: systematic review and meta-analysis. J Hypertens (2015) 0.77
Intensive blood pressure control in obese diabetic patients: clinical relevance of stroke prevention in the ACCORD trial. Expert Rev Cardiovasc Ther (2012) 0.77
Thyroid nodule morphology affects the efficacy of ultrasound-guided interstitial laser ablation: a nested case-control study. Int J Hyperthermia (2014) 0.77
Neutrophil count for the identification of postmenopausal hypertensive women at increased cardiovascular risk. Obstet Gynecol (2010) 0.77
Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension. Expert Opin Drug Metab Toxicol (2013) 0.76
Blood pressure lowering in diabetic patients. J Hypertens (2012) 0.76
Ultrasound-guided interstitial laser ablation for thyroid nodules is effective only at high total amounts of energy: results from a three-year pilot study. Surg Innov (2012) 0.76
Modernization and hypertension: is the link changing? Hypertens Res (2013) 0.76
Very early initiation of statin therapy and mortality in patients with acute coronary syndrome. Acute Card Care (2012) 0.76
The optimal blood pressure target for patients with coronary artery disease. Curr Cardiol Rep (2010) 0.76
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together? Curr Vasc Pharmacol (2010) 0.76
Echocardiographic left ventricular hypertrophy: implications for clinicians. J Hypertens (2012) 0.75
Microcirculation and left-ventricular hypertrophy. J Hypertens (2012) 0.75
Response to morning surge, dipping, and sleep-time blood pressure as prognostic markers of cardiovascular risk. Hypertension (2013) 0.75
Hypertension and the J-curve phenomenon: implications for tight blood pressure control. Hypertens Res (2012) 0.75
Lowering blood pressure with β-blockers in peripheral artery disease: the importance of comorbidity. J Hypertens (2011) 0.75
Protein intake in type 1 diabetes: putting controversies into perspectives. J Hypertens (2013) 0.75
Interpretation of ambulatory blood pressure profile: a prognostic approach for clinical practice. J Hypertens (2015) 0.75
Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents. Hypertens Res (2011) 0.75